Chongqing Zhifei Biological Products Co., Ltd. (SHE:300122)
China · Delayed Price · Currency is CNY 16.90
-0.17 (-1.00%)
At close: Feb 13, 2026
SHE:300122 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 10,687 | 25,846 | 52,914 | 38,260 | 30,629 | 15,156 |
Other Revenue | 223.28 | 223.28 | 4.08 | 3.85 | 23.46 | 34.23 |
| 10,911 | 26,070 | 52,918 | 38,264 | 30,652 | 15,190 | |
Revenue Growth (YoY) | -70.05% | -50.73% | 38.30% | 24.83% | 101.79% | 43.48% |
Cost of Revenue | 8,203 | 18,971 | 38,986 | 25,518 | 15,728 | 9,316 |
Gross Profit | 2,707 | 7,099 | 13,932 | 12,746 | 14,925 | 5,875 |
Selling, General & Admin | 2,698 | 3,045 | 3,166 | 2,595 | 2,121 | 1,410 |
Research & Development | 898.65 | 971.37 | 968.47 | 854.16 | 552.63 | 299.65 |
Other Operating Expenses | 89.1 | 135.45 | 238.75 | 177.02 | 135.23 | 70.99 |
Operating Expenses | 4,068 | 4,761 | 4,725 | 4,047 | 3,000 | 1,863 |
Operating Income | -1,361 | 2,338 | 9,206 | 8,698 | 11,924 | 4,011 |
Interest Expense | -296.38 | -146.85 | -81 | -53.3 | -56.14 | -127.14 |
Interest & Investment Income | 29.79 | 66.63 | 67.94 | 46.09 | 61.47 | 11.98 |
Currency Exchange Gain (Loss) | 1.67 | 1.67 | 2.28 | 15.4 | -10.1 | 3.84 |
Other Non Operating Income (Expenses) | -2.57 | -37.32 | -36.56 | -22.64 | -17.23 | -19.61 |
EBT Excluding Unusual Items | -1,629 | 2,222 | 9,159 | 8,684 | 11,902 | 3,880 |
Gain (Loss) on Sale of Investments | -7.9 | - | - | - | -5.63 | -13.33 |
Gain (Loss) on Sale of Assets | 5.44 | 0.05 | 41.37 | 0.01 | 0.04 | -0 |
Asset Writedown | -99.39 | -0.36 | -0.13 | -0.09 | -1.68 | -0.55 |
Other Unusual Items | 59.04 | 32.05 | 142.34 | 34.31 | 35.83 | -12.34 |
Pretax Income | -1,671 | 2,254 | 9,342 | 8,718 | 11,931 | 3,854 |
Income Tax Expense | -376.34 | 235.21 | 1,272 | 1,179 | 1,723 | 552.75 |
Net Income | -1,310 | 2,018 | 8,070 | 7,539 | 10,209 | 3,301 |
Net Income to Common | -1,310 | 2,018 | 8,070 | 7,539 | 10,209 | 3,301 |
Net Income Growth | - | -74.99% | 7.04% | -26.15% | 209.23% | 39.51% |
Shares Outstanding (Basic) | 2,395 | 2,395 | 2,400 | 2,400 | 2,400 | 2,400 |
Shares Outstanding (Diluted) | 2,395 | 2,395 | 2,400 | 2,400 | 2,400 | 2,400 |
Shares Change (YoY) | -0.00% | -0.20% | - | - | -0.00% | 0.00% |
EPS (Basic) | -0.55 | 0.84 | 3.36 | 3.14 | 4.25 | 1.38 |
EPS (Diluted) | -0.55 | 0.84 | 3.36 | 3.14 | 4.25 | 1.38 |
EPS Growth | - | -74.94% | 7.04% | -26.15% | 209.23% | 39.50% |
Free Cash Flow | 991.69 | -5,344 | 7,862 | 535.93 | 6,575 | 2,670 |
Free Cash Flow Per Share | 0.41 | -2.23 | 3.28 | 0.22 | 2.74 | 1.11 |
Dividend Per Share | - | 0.200 | 0.800 | 0.333 | 0.400 | 0.333 |
Dividend Growth | - | -75.00% | 140.02% | -16.68% | 20.01% | - |
Gross Margin | 24.81% | 27.23% | 26.33% | 33.31% | 48.69% | 38.67% |
Operating Margin | -12.47% | 8.97% | 17.40% | 22.73% | 38.90% | 26.41% |
Profit Margin | -12.00% | 7.74% | 15.25% | 19.70% | 33.30% | 21.73% |
Free Cash Flow Margin | 9.09% | -20.50% | 14.86% | 1.40% | 21.45% | 17.57% |
EBITDA | -943.42 | 2,710 | 9,518 | 9,003 | 12,297 | 4,132 |
EBITDA Margin | -8.65% | 10.40% | 17.99% | 23.53% | 40.12% | 27.20% |
D&A For EBITDA | 417.6 | 372.28 | 311.85 | 304.88 | 372.24 | 120.93 |
EBIT | -1,361 | 2,338 | 9,206 | 8,698 | 11,924 | 4,011 |
EBIT Margin | -12.47% | 8.97% | 17.40% | 22.73% | 38.90% | 26.41% |
Effective Tax Rate | - | 10.44% | 13.62% | 13.52% | 14.44% | 14.34% |
Revenue as Reported | 10,911 | 26,070 | 52,918 | 38,264 | 30,652 | 15,190 |
Advertising Expenses | - | 395.29 | 475.81 | 395.05 | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.